verified SJR 0,694 · Q2 • database Scopus / SJR & Web of Science indexed

United Kingdom · Springer Nature

workspace_premium Q2 — Genetics lock_open Open Access

The Pharmacogenomics Journal

The Pharmacogenomics Journal is a journal indexed in SJR in Genetics and Pharmacology with an H index of 99. It has a price of 3190 €. It has an SJR impact factor of 0,694 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,694.

ISSN: 1470-269X

Publisher: Springer Nature

Category: Genetics

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,694 Q2

H-index 99

Acceptance rate pie_chart

25% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.190 € Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,694

H-index

Docs (year)

Docs 3y

134

Total refs

1754

Cites 3y

367

Citable 3y

134

Cites/Doc 2y

2.86

Ref/Doc

44.97

Immediate OA

3190 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Bioinformatics in a post-genomics world - the need for an inclusive approach

Will pharmacogenomics guide clinical practice?

Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite

Cytoprotection against thermal injury: evaluation of herbimycin A by cell viability and cDNA arrays

CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians

Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy

Comprehensive expression analysis of a rat depression model

Complexity and Pharmacogenomics

Clinical implications of pharmacogenomics for tardive dyskinesia

Cebus apella, a nonhuman primate highly susceptible to neuroleptic side effects, carries the GLY9 dopamine receptor D3 associated with tardive dyskinesia in humans

CAR/PXR provide directives for Cyp3a41 gene regulation differently from Cyp3a11

Can nature's defence against malaria be mimicked by the development of host-directed therapies?

SHOW MORE ARTICLES

Both populations and individuals are evolutionary targets: pharmacogenomic and cultural indicators

A functional C-G polymorphism in the CYP7B1 promoter region and its different distribution in Orientals and Caucasians

Association study of myo-inositol monophosphatase 2 (IMPA2) polymorphisms with bipolar affective disorder and response to lithium treatment

Association between methylenetetrahydrofolate reductase polymorphisms and the relapse of acute lymphoblastic leukemia: a meta-analysis

Association between a G-protein beta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders

Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism

An international database and integrated analysis tools for the study of cancer gene expression

Age at onset: important marker of genetic heterogeneity in Alzheimer's disease

Advances in the pharmacogenomics of adverse drug reactions

A unique mouse model for succinic semialdehyde dehydrogenase deficiency with implications for gamma hydroxybutyrate intoxication

A regulatory protocol for pharmacogenomics services

A multi-marker molecular signature approach for treatment-specific subgroup identification with survival outcomes

FAQs

The Pharmacogenomics Journal has an SJR of 0,694 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is 3190 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for The Pharmacogenomics Journal is 25%.

The Pharmacogenomics Journal

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of The Pharmacogenomics Journal?

What is the APC / publication cost?

What is the acceptance rate?